文献速递前列腺增生与排尿功能障碍

内镜下尿道内切开联合病灶内注射丝裂霉素C治疗复发性球部及球膜部尿道狭窄

Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures.
PubMed 文献 · Urology · 2017-07-20

回顾性分析44例复发性球部及球膜部尿道狭窄患者(放射性18例、非放射性26例),接受直视下尿道内切开联合丝裂霉素C注射及术后1个月清洁间歇导尿。中位随访25.8个月,75.0%患者无需再次手术,放射性组66.7%、非放射性组80.8%。无长期并发症归因于丝裂霉素C,作者认为该法安全且早期结果有前景。

要点

  • 44例复发性球部/球膜部狭窄患者中,75.0%(33/44)在中位随访25.8个月内无需再次手术。
  • 放射性狭窄组无需再次手术比例为66.7%(12/18),非放射性组为80.8%(21/26)。
  • 复发者中位复发时间10.7个月,放射性组9.4个月,非放射性组11.2个月。

核心结论

  • 作者认为,对复发性、短段球部及球膜部尿道狭窄,直视下尿道内切开联合丝裂霉素C及短期清洁间歇导尿是一种安全的内镜方式,早期结果有前景。
  • 作者认为,该方法对开放重建条件不佳的患者可能有用。

研究设计与样本

  • 回顾性数据库分析,纳入2011年至2016年在一家三级医疗中心连续就诊的复发性球部及球膜部尿道狭窄患者,共44例,其中放射性狭窄18例、非放射性狭窄26例。
  • 所有患者既往内镜治疗或尿道成形术失败。
  • 手术方式为在12点、3点、9点位置冷刀切开,随后病灶内注射10 mL丝裂霉素C(0.4 mg/mL),以0.2-0.4 mL分次注射,术后每日清洁间歇导尿1个月。

主要发现

  • 中位狭窄长度2.0 cm(四分位距1.0-2.5)。
  • 中位随访25.8个月(四分位距12.9-47.2),75.0%(33/44)患者无需额外手术干预,放射性组12/18(66.7%),非放射性组21/26(80.8%)。
  • 复发者中位复发时间10.7个月(四分位距3.9-17.6),放射性组9.4个月(四分位距3.5-17.6),非放射性组11.2个月(四分位距8.0-25.6)。
  • 4例患者(放射性组2例、非放射性组2例)因复发选择尿道成形术;其余复发者(7例)接受第二次直视下尿道内切开联合丝裂霉素C,总体37/40(92.5%)无需进一步手术,放射性组14/16(87.5%),非放射性组23/24(95.8%)。
  • 无长期并发症归因于丝裂霉素C。

临床怎么用

  • 作者认为,直视下尿道内切开联合丝裂霉素C及短期清洁间歇导尿可用于复发性、短段球部及球膜部尿道狭窄,早期结果有前景。
  • 作者认为,该方法对开放重建条件不佳的患者可能有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe our experience with direct visual internal urethrotomy (DVIU) and mitomycin C (MMC) for recurrent bulbar and bulbomembranous urethral strictures of radiation and non-radiation-induced etiologies. METHODS: We reviewed our database of consecutive patients presenting to our tertiary care institution with recurrent bulbar and bulbomembranous urethral strictures who underwent DVIU with MMC from 2011 to 2016. Patients were stratified by radiation-induced strictures (RIS) vs non-RIS. Cold-knife incisions were made at 12-, 3-, and 9-o'clock positions followed by intralesional injection of 10 mL MMC (0.4 mg/mL) in 0.2-0.4 mL aliquots and 1 month of postoperative daily clean intermittent catheterization (CIC). RESULTS: All 44 patients (RIS n = 18, non-RIS n = 26) failed prior endoscopic management or urethroplasty. Median stricture length was 2.0 cm (interquartile range [IQR] 1.0-2.5). Over a median follow-up of 25.8 months (IQR 12.9-47.2), 75.0% of patients (33/44) required no additional surgical intervention (RIS 12/18, 66.7%; non-RIS 21/26, 80.8%). Median time to stricture recurrence among those who recurred was 10.7 months (IQR 3.9-17.6; RIS 9.4 months, IQR 3.5-17.6; non-RIS 11.2 months, IQR 8.0-25.6). Four patients (RIS n = 2, non-RIS n = 2) elected to undergo urethroplasty for recurrence. A second DVIU with MMC was performed in the remaining recurrences (n = 7) with no further surgical intervention required in 37 of 40 of patients (92.5%) overall (RIS 14/16, 87.5%; non-RIS 23/24, 95.8%). No long-term complications were attributable to MMC. CONCLUSION: DVIU with MMC and short-term CIC for recurrent, short, bulbar and bulbomembranous urethral strictures is a safe endoscopic modality with promising early results. This approach may be useful for patients who are suboptimal candidates for open reconstruction.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Farrell MR, Lawrenz CW, Levine LA, et al. Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures. Urology. 2017. PMID: 28735714. doi:10.1016/j.urology.2017.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。